ZIM LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.2 INR | +1.11% |
|
+2.83% | +2.60% |
| May. 14 | Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5% | MT |
| May. 13 | ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 3.34B 39.94M | Sales 2023 | 3.99B 47.74M | Capitalization | 3.53B 42.25M |
|---|---|---|---|---|---|
| Net income 2022 | 146M 1.75M | Net income 2023 | 244M 2.92M | EV / Sales 2022 | 0.93 x |
| Net Debt 2022 | 499M 5.98M | Net Debt 2023 | 557M 6.68M | EV / Sales 2023 | 1.02 x |
| P/E ratio 2022 |
17.8
x | P/E ratio 2023 |
14.5
x | Employees | 525 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.62% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | -1.47% | ||
| 1 week | -0.38% | ||
| Current month | -3.40% | ||
| 1 month | +20.82% | ||
| 3 months | +5.89% | ||
| 6 months | -3.19% | ||
| Current year | +1.48% |
1 week
110.75
122.35
1 month
91.60131.30
Current year
89.90131.30
1 year
86.65151.75
3 years
27.67151.75
5 years
14.00151.75
10 years
14.00151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Anwar Siraj Daud
CEO | Chief Executive Officer | - | 89-12-31 |
| Director of Finance/CFO | - | 19-03-31 | |
| Director of Finance/CFO | - | 90-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anwar Siraj Daud
CEO | Chief Executive Officer | - | 89-12-31 |
| Director of Finance/CFO | - | 90-12-31 | |
Prakash Sapkal
COO | Chief Operating Officer | - | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 118.2 | +1.11% | 14 597 |
| 24-05-14 | 117 | -1.47% | 158,744 |
| 24-05-13 | 118.7 | +3.17% | 85,397 |
| 24-05-10 | 115 | +2.45% | 34,268 |
| 24-05-09 | 112.3 | -2.35% | 4,068 |
Delayed Quote Bombay S.E., May 14, 2024 at 06:00 am EDT
More quotes
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Sector
Pharmaceuticals
Calendar
02:30am
- Q4 2024 Earnings Call
| 1st Jan change | Capi. | |
|---|---|---|
| +1.48% | 69.25M | |
| +22.69% | 43.81B | |
| +26.19% | 23.01B | |
| +18.00% | 15.27B | |
| +8.91% | 13.68B | |
| +42.72% | 11.96B | |
| -6.14% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.59B |
- Stock Market
- Equities
- 541400 Stock
